Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters











Database
Language
Publication year range
1.
Regul Toxicol Pharmacol ; 140: 105364, 2023 May.
Article in English | MEDLINE | ID: mdl-36907371

ABSTRACT

Opinion to be cited as: SCCS (Scientific Committee on Consumer Safety), Opinion on Acid Yellow 3 - C054 (CAS Number 8004-92-0, EC No 305-897-5), submission II, preliminary version of 7 May 2021, final version of 23 July 2021, SCCS/1631/21.


Subject(s)
Cosmetics , Risk Assessment , Consumer Product Safety , Attitude
2.
Regul Toxicol Pharmacol ; 138: 105312, 2023 Feb.
Article in English | MEDLINE | ID: mdl-36565917

ABSTRACT

OPINION TO BE CITED AS: SCCS (Scientific Committee on Consumer Safety), scientific opinion on Butylated hydroxytoluene (BHT), preliminary version of September 27, 2021, final version of December 2, 2021, SCCS/1636/21.


Subject(s)
Butylated Hydroxytoluene , Cosmetics , Risk Assessment , Consumer Product Safety , Attitude
3.
Regul Toxicol Pharmacol ; 126: 105046, 2021 Nov.
Article in English | MEDLINE | ID: mdl-34560169

ABSTRACT

The Cosmetic Regulation (EC) No 1223/2009 specifically covers the risk of nanomaterials used in cosmetic products. If there are concerns regarding the safety of a nanomaterial, the European Commission refers it to the SCCS for a scientific opinion. The Commission mandated the SCCS to identify the scientific basis for safety concerns that could be used as a basis for identifying and prioritising nanomaterials for safety assessment, and to revisit previous inconclusive SCCS opinions on nanomaterials to identify any concerns for potential risks to the consumer health. The SCCS Scientific Advice identified the key general aspects of nanomaterials that should raise a safety concern for a safety assessor/manager, so that the nanomaterial(s) in question could be subjected to safety assessment to establish safety to the consumer. The Advice also developed a list of the nanomaterials notified to the Commission for use in cosmetics in an order of priority for safety assessment, and revisited three previous inconclusive opinions on nanomaterials to highlight concerns over consumer safety that merited further safety assessment.


Subject(s)
Consumer Product Safety/standards , Cosmetics/adverse effects , Nanostructures/adverse effects , Dose-Response Relationship, Drug , Europe , Humans , Particle Size , Risk Assessment , Solubility , Surface Properties
4.
Toxicology ; 436: 152421, 2020 04 30.
Article in English | MEDLINE | ID: mdl-32119890

ABSTRACT

Although the need for non-animal alternatives has been well recognised for the human health hazard assessment of chemicals in general, it has become especially pressing for cosmetic ingredients due to the full implementation of testing and marketing bans on animal testing under the European Cosmetics Regulation. This means that for the safety assessment of cosmetics, the necessary safety data for both the ingredients and the finished product can be drawn from validated (or scientifically-valid), so-called "Replacement methods". In view of the challenges for safety assessment without recourse to animal test data, the Methodology Working Group of the Scientific Committee on Consumer Safety organised a workshop in February 2019 to discuss the key issues in regard to the use of animal-free alternative methods for the safety evaluation of cosmetic ingredients. This perspective article summarises the outcomes of this workshop and reflects on the state-of-the-art and possible way forward for the safety assessment of cosmetic ingredients for which no experimental animal data exist. The use and optimisation of "New Approach Methodology" that could be useful tools in the context of the "Next Generation Risk Assessment" and the strategic framework for safety assessment of cosmetics were discussed in depth.


Subject(s)
Animal Testing Alternatives/trends , Cosmetics/adverse effects , Toxicity Tests/trends , Animals , Computer Simulation , Consumer Product Safety , Cosmetics/classification , Cosmetics/pharmacokinetics , Diffusion of Innovation , European Union , Forecasting , Humans , Models, Biological , Risk Assessment , Structure-Activity Relationship
SELECTION OF CITATIONS
SEARCH DETAIL